Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Visgenx: Taking retinal gene therapy beyond rare disease

First program delivers an enzyme involved in the fatty acid synthesis pathway for patients with dry AMD

By Danielle Golovin, Senior Biopharma Analyst
April 26, 2024 11:07 PM UTC

Visgenx is delivering a gene therapy to restore expression of an enzyme involved in a fatty acid pathway that the company believes could slow or stop progressive vision loss in patients with age-related macular degeneration.

The strategy represents a departure from the more common use of gene therapy — to deliver a functional copy of a gene that’s mutated in a rare and severe genetic disorder. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

University of California Irvine

University of California San Diego

Visgenx Inc.